Jay Stevens, MD
Internal Medicine · Franklin, PANPI 1760461834
Payments from drug & device makers
Across 152 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$497
- Lilly USA, LLC$333
- AstraZeneca$265
- Boehringer Ingelheim$249
- Pfizer$129
- Merck$126
- plus $905 from 19 others
What the payments were for
- Food & beverage$2,497100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $497 |
| Lilly USA, LLC | 21 | $333 |
| AstraZeneca | 15 | $265 |
| Boehringer Ingelheim | 14 | $249 |
| Pfizer | 9 | $129 |
| Merck | 8 | $126 |
| Amgen | 6 | $100 |
| E.r. Squibb & Sons, L.L.C. | 6 | $93 |
| GSK | 6 | $89 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $73 |
| Novartis | 3 | $66 |
| Verona Pharma, Inc. | 3 | $61 |
| AbbVie(2 entities) | 4 | $58 |
| Sunovion Pharmaceuticals Inc. | 2 | $56 |
| Amarin Pharma, Inc. | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Exact Sciences | 2 | $45 |
| Astellas Pharma US Inc | 2 | $33 |
| Johnson & Johnson | 2 | $33 |
| Lundbeck LLC | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Abbott | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$2,505 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 709 | $383,422 |
| OzempicSemaglutide | 303 | $303,891 |
| JardianceEmpagliflozin | 319 | $302,511 |
| MounjaroTirzepatide | 131 | $154,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 177 | $119,616 |
| XareltoRivaroxaban | 122 | $101,806 |
| TrulicityDulaglutide | 47 | $46,797 |
| OtezlaApremilast | 16 | $38,419 |
| MyrbetriqMirabegron | 50 | $30,411 |
| EntrestoSacubitril/Valsartan | 32 | $29,991 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $22,922 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 77 | $22,326 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 42 | $21,074 |
| FarxigaDapagliflozin Propanediol | 21 | $19,691 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 181 | $19,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $129 | $383,422709 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $249 | $335,191382 claims |
| Novo NordiskOzempic, Rybelsus | $497 | $322,303323 claims |
| Lilly USA, LLCMounjaro, Trulicity | $333 | $201,159178 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $89 | $149,486234 claims |
| Johnson & JohnsonXarelto | $33 | $101,806122 claims |
| AmgenOtezla | $100 | $38,41916 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $30,41150 claims |
| NovartisEntresto | $66 | $29,99132 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $12 | $28,54881 claims |
| AstraZenecaFarxiga | $265 | $19,69121 claims |
| AbbVieLinzess | $58 | $7,45013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Franklin
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.